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Abstract
Mycinamicin, a 16-membered macrolide antibiotic produced by Micromonospora
griseorubida, comprises a macrolactone and two deoxysugars: desosamine and
mycinose. Mycinose is synthesized through two modification steps: the methyla-
tion of 6-deoxyallose in mycinamicin VI and of javose in mycinamicin III. To
confirm the role of mycE and mycF genes in mycinamicin biosynthesis in
M. griseorubida, disruption mutants of mycE and mycF were constructed by
disruption plasmids containing attB in the disruption cassette FRT-neo-oriT-
FRT-attB for the integration of fC31-derivative vector plasmids; the disruption
mutants were complemented through the integration of pSET152 derivatives
containing intact mycE or mycF into the artificially inserted attB site. These
disruption mutants did not produce mycinamicin II, but mainly accumulated
mycinamicins VI and III, indicating that MycE and MycF methylated the C200-OH
group of 6-deoxyallose in mycinamicin VI and the C300-OH group of C200-
methylated 6-deoxyallose in mycinamicin III, respectively. The complemented
strains of mycE and mycF recovered the mycinamicin II productivity.
Introduction
In general, to confirm the function of a gene in a micro-
organism, the mutant with a disrupted gene should be
isolated, and genetic complementation studies for the
mutant should be performed. Recently, a simple and highly
efficient PCR-targeting method was developed with the
phage l-Red recombinase to disrupt chromosomal genes in
Escherichia coli in which PCR primers provide the homology
to the targeted gene (Datsenko & Wanner, 2000), and a
modified system was also developed for gene targeting of
Streptomyces strains with a disruption cassette, which con-
tained an oriT region with a selectable antibiotic resistance
gene to efficiently transfer a targeted plasmid from E. coli to
Streptomyces by intergeneric conjugation (Gust et al., 2003).
In Streptomyces strains, genetic complementation studies
could be performed with transconjugation vectors, posses-
sing a fC31 int gene and an attP site, that were site
specifically inserted into the fC31 attB attachment site of a
host chromosome. The attB site is distributed widely
throughout Streptomyces strains, but there are few reports
regarding the attB site of non-Streptomyces actinomycetes
(Anzai et al., 2009). Saccharopolyspora erythraea, which
produces erythromycin, does not possess the fC31 attB site
on its chromosome; the site was artificially introduced into
the chromosome for antibiotic production using a combi-
natorial biosynthesis technique (Rodriguez et al., 2003).
Mycinamicin, which is produced by Micromonospora
griseorubida A11725, is a 16-membered macrolide antibiotic
with strong antibacterial activity against gram-positive bac-
teria (Satoi et al., 1980). Mycinamicin consists of a macro-
lactone substituted with two different sugars: desosamine
and mycinose. The nucleotide sequence of the complete
mycinamicin biosynthetic gene cluster has been reported
(Anzai et al., 2003), wherein two putative O-methyltransfer-
ase (OMT) genes mycE and mycF were identified. It was
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reported previously by Inouye et al. (1994) that mycinami-
cin III (M-III) was converted to mycinamicin IV (M-IV) by
the crude E. coli cell extract overexpressed MycF protein.
Moreover, the in vitro functions of MycE and MycF proteins
were characterized using the purified MycE and MycF
proteins overexpressed in E. coli cells (Li et al., 2009;
Fig. 1). The purified MycE and MycF proteins methylated
the C200-OH group of 6-deoxyallose in mycinamicin VI (M-
VI) and the C300-OH group of javose (i.e. C200-methylated 6-
deoxyallose) in M-III, respectively. Here, we have demon-
strated the isolation and characterization of mycE and mycF
disruption mutants obtained from M. griseorubida A11725,
which would not possess the fC31 attB site on the chromo-
some, by the disruption cassette FRT-neo-oriT-FRT-attB
and the genetic complemented strains, in which plasmids
including each OMT gene – mycE or mycF – were inserted
into the artificially inserted attB site.
Materials and methods
Strains, media, and culture conditions
The strains used in this study are shown in Table 1. The
culture conditions of M. griseorubida and E. coli were
according to our previous report (Anzai et al., 2004a).
FMM broth containing 7% dextrin, 0.5% glucose, 0.5%
yeast extract, 0.5% soybean meal (Ajinomoto, Japan), 0.5%
CaCO3, 0.1% K2HPO4, 0.4% MgSO4  7H2O, and 0.0002%
CoCl2  6H2O was used for fermentation of M. griseorubida.
Vectors, DNA manipulation, PCR, and Southern
blot
The vectors used in this study are shown in Table 1. TaKaRa
ExTaqs (TaKaRa, Japan) and PfuTurbos (Stratagene) DNA
polymerase used for the DNA fragment were amplified by
PCR. Plasmid and genomic DNA amplification, restriction
enzyme digestion, fragment isolation, cloning, and DNA
fragment amplification were performed according
to standard procedures. Southern blot analysis was per-
formed according to our previous procedure (Anzai et al.,
2004a).
Construction of the gene disruption cassette
FRT-neo-oriT-FRT-attB
Using pIJ776 containing FRT-neo-oriT-FRT as the template,
the gene disruption cassette FRT-neo-oriT-FRT-attB was
amplified by PfuTurbos DNA polymerase with the primers
FRTF1attB containing the sequence of the bacteriophage
fC31 attB attachment site and FRTR (Table 2). The PCR
fragment was cloned into the EcoRV site of pLITMUS38 to
generate pMG501.
Construction of plasmids
The mycE-disrupted plasmid, pMG502, was constructed
using three restriction fragments (3.2 kb BamHI–MluI,
0.7 kb MluI–EcoRI, and 3.8 kb StuI–BamHI) derived from
pMR01, and the 1.5-kb EcoRV fragment containing the
disruption cassette FRT-neo-oriT-FRT-attB derived from
pMG501. The 9.5-kb DNA fragment linking these three
restriction fragments and the disruption cassette together
was inserted into the BglII and EcoRI sites on pSAN-lac to
create pMG502. To generate pMG503 whose neo gene was in
the opposite direction from the mycinose biosynthesis gene
cluster, the 1.3-kb XbaI fragment including neo and oriT
derived from pMG501 was ligated with the 15-kb XbaI
fragment derived from pMG502.
To construct pMG504 containing myrB, mycG, mycF,
mycCI, and mycCII, the 2.4-kb BsiWI–StuI and 3.8-kb
StuI–MluI fragments obtained from pMR01 were cloned
into pLITMUS28 and pLITMUS38, respectively; then, the
2.4-kb BglII–StuI and 3.8-kb StuI–SpeI fragments derived
from these resulting plasmids were inserted into the BglII
and XbaI sites on pSAN-lac. The mycF region on pMG504
was replaced with the disruption cassette FRT-neo-oriT-
FRT-attB using the l-Red-mediated recombination system
according to Gust et al. (2003). The cassette was amplified
by PCR with the primers mycFendF and mycFendR using
the 1.5-kb EcoRV fragment from pMG501 as a template
DNA. Escherichia coli BW25113/pIJ790 cells containing
pMG504 were transformed with the amplified cassette by
electroporation. The resulting transformants were charac-
terized by PCR with a set of oligonucleotides (mycFF and
mycFCIendR) priming outside of the recombination region,




M-VI M-III6-deoxyallose javose M-IVmycinose
Fig. 1. Function of MycE and MycF in mycinamicin biosynthesis. PML-IV, protomycinolide IV; M-VI, mycinamicin VI; M-III, mycinamicin III; M-IV,
mycinamicin IV; and M-II, mycinamicin II.
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Table 1. Strains and plasmids used in this study
Strain/plasmid Relevant genotype/comments Source or reference
M. griseorubida
A11725 Wild type, mycinamicin producer Satoi et al. (1980)
TPMA0003 DmycE: aa6-393 replaced with an oriT-neo-attB cassette This study
TPMA0004 DmycF: aa2-253 replaced with an oriT-neo-attB cassette This study
TPMA0006 pMG507 including a mycE-controlled mycCI promoter mycCIp induced in mycE deletion
mutant TPMA0003
This study
TPMA0009 pMG508 including mycF induced in the mycF deletion mutant TPMA0004 This study
TPMA0014 DmycE: aa6-393 replaced with a neo-oriT-attB cassette This study
TPMA0016 DmycF: aa2-253 replaced with a neo-oriT- attB cassette This study
E. coli
S17-1 Conjugation donor American Type
Culture Collection
BW25113 K12 derivative: DaraBAD, DrhaBAD Gust et al. (2003)
JM109 General cloning host
Plasmids
pIJ790 l-Red (gam, bet, exo), cat, araC, rep101ts Gust et al. (2003)
pIJ776 Source of neo-oriT for pMG501 K.F. Chater,
(pers. commun.)
pLITMUS28 Cloning vector: bla NewEngland BioLabs
pLITMUS38 Cloning vector: bla NewEngland BioLabs
pDrive TA-cloning vector: bla, aph Qiagen
pSET152 aac(3)IV(Aprar), oriT, attP, int Kieser et al. (2000)
pSAN-lac bla, tsr Arisawa et al. (1995)
pMR01 Cosmid clone that contains some mycinose biosynthesis genes including mycE and mycF Anzai et al. (2003)
pMG501 1.5-kb FRT-neo-oriT-FRT-attB cassette inserted into pLITMUS38 This study
pMG502 9.5-kb fragment containing a mycinose biosynthetic gene cluster region replacing mycE
with a FRT-neo-oriT-FRT-attB cassette inserted into pSAN-lac
This study
pMG503 9.5-kb fragment containing a mycinose biosynthetic gene cluster region replacing mycE
with an FRT-neo-oriT-FRT-attB cassette inserted into pSAN-lac
This study
pMG504 6.9-kb fragment containing myrB, mycG, mycF, mycCI, and mycCII inserted into pSAN-lac This study
pMG505 mycF replaced with a FRT-neo-oriT-FRT-attB cassette on pMG504 This study
pMG506 mycF replaced with an FRT-neo-oriT-FRT-attB cassette on pMG504 This study
pMG507 mycE-controlled mycCI promoter mycCIp inserted into pSET152 This study
pMG508 1.4-kb BamHI–EcoRI fragment including mycF inserted into pSET152 This study
Table 2. PCR primers used in this study
















Bacteriophage fC31 attB site was bold. The unique priming site P1 and P2 of disruption cassette FRT-neo-oriT-FRTon pIJ776 and the unique priming site
5’-end of attB and P2 of disruption cassette FRT-neo-oriT-FRT-attB on pMG501 are lowercase. The relevant restriction sites for genetic manipulation are
underlined.
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mycF gene. To generate pMG506 whose neo gene was in the
same direction as the disrupted mycF gene, the 1.3-kb XbaI
fragment including neo and oriT derived from pMG501 was
ligated with the 12-kb XbaI fragment derived from pMG505.
pMG507 and pMG508 were constructed to perform the
genetic complementation studies for mycE and mycF dis-
ruption mutants, respectively. The mycCI gene promoter
region, mycCIp, was amplified by PCR with the primers
mycCIPFNh and mycCIPRNd; the protein-coding region
of mycE was also amplified with the primers mycEFNd
and mycERBam. After determining the sequences of these
amplified fragments, the 0.5-kb NheI–NdeI fragment that
included the mycCIp region along with the 1.2-kb NdeI–
BamHI fragment coding mycE were inserted into the XbaI
and BamHI sites on pSET152 to generate pMG507. To
construct pMG508, the 1.4-kb BamHI–EcoRI fragment
derived from pMR01 was cloned into pSET152.
Conjugation procedure
The intergeneric conjugation from E. coli S17-1 to
M. griseorubida was performed using a modified protocol
of our previous procedure (Anzai et al., 2004a). A mixture of
the E. coli donor cells and the M. griseorubida recipient cells
was spread on MR0.1S plates or AS-1 agar plates (Alexander
et al., 2003). The plates were incubated at 32 1C for 20–24 h
and then overlaid with 1 mL water containing 500mg of
nalidixic acid to inhibit further growth of E. coli and 1 mg of
neomycin or apramycin for selecting the M. griseorubida
exconjugants. The plates were then reincubated at 32 1C for
7–10 days for the growth of the exconjugants. The genetic
conditions of the exconjugants were confirmed by PCR and
Southern hybridization. The result of Southern blot analysis
is shown in Supporting Information.
Production and analysis of mycinamicins
Micromonospora griseorubida was cultured in 5 mL MR0.1S
broth or FMM broth with the appropriate antibiotics on a
rotary shaker (150 r.p.m.) at 27 1C for 10 days. The broth was
adjusted to pH 9–11 with 28% ammonia solution and
extracted twice with an equal volume of ethyl acetate
(EtOAc); the extract was then concentrated in vacuo. The
crude extracts were dissolved with EtOAc, and then an equal
volume of 0.1% trifluoroacetic acid (TFA) was added. The
water layer containing mycinamicins was adjusted to pH
9–11 with 28% ammonia solution and extracted with an
equal volume of EtOAc. The organic layer was concentrated
in vacuo, and each residue was dissolved in MeOH for HPLC
and liquid chromatography (LC-MS) analyses. HPLC analysis
scanning was performed using a diode array detector model
L-2450 (Hitachi, Japan) under the following conditions:
ODS-80TM, i.d. = 150 4.6 mm (Toso Co., Japan); MeCN,
0.06% TFA (30 : 70); flow rate, 0.8 mL min1; and UV wave-
length, 200–300 nm. LC-MS analysis was performed on
LCMS2010 (Shimadzu) using reverse-phase HPLC [STR
ODS-II, i.d. = 150 2.0 mm; MeCN, 0.06% TFA (35 : 65);
flow rate, 0.2 mL min1; and UV wavelength, 220 nm]. Stan-
dard compounds of M-II, M-III, and M-VI were obtained
from the fermentation broth of M. griseorubida A11725.
Results
Disruption and complementation of the mycE
gene
The disruption cassette FRT-neo-oriT-FRT-attB was used to
obtain the mycE disruption mutant of M. griseorubida. In
previous studies, the transconjugant of M. griseorubida has
never been isolated with pSET152 as an intergeneric con-
jugation vector. Therefore, we estimated that M. griseorubida
would not possess the bacteriophage fC31 attB site on the
chromosome. The mycE-deleted plasmid pMG502, which
had the mycinose biosynthetic gene cluster region in which
mycE was replaced with the disruption cassette, was gener-
ated with pSAN-lac as the suicide vector. pSAN-lac was
constructed with pUC18 and pIJ350 as an E. coli–Strepto-
myces shuttle vector, but the plasmid has never been
amplified in M. griseorubida cells (data not shown). Plasmid
pMG502 was transferred from E. coli to M. griseorubida
A11725 by intergeneric conjugation, and some neomycin-
resistant (neor) and thiostrepton-sensitive (thios) transcon-
jugants were isolated. PCR was used to verify that the
chromosomal copy of A11725 mycE was deleted by double
cross-over. Using the primers mycEF and mycERBam an-
nealing outside the disruption cassette, the 1.4- and 1.2-kb
amplified fragments were observed in TPMA0014 and the
wild strain A11725, respectively (Fig. 2b). The size difference
indicated that TPMA0014 was the mycE disruption mutant.
M-VI was detected in the EtOAc extract from the FMM
culture broth of TPMA0014 at 7.63 min (Fig. 3). However,
the productivity of M-VI by TPMA0014 was very low
(0.08mg mL1), and it was estimated that the direction of
neo gene transcription had a negative effect on the produc-
tivity. We also isolated another mycE disruption mutant in
which the direction of the neo gene was opposite to the
mycinose biosynthesis gene cluster. The neor and thios
transconjugant TPMA0003, which was isolated by the
introduction of pMG503 into A11725, was confirmed to be
a mycE disruption mutant by PCR (Fig. 2b); the M-VI
productivity (13.8mg mL1) of TPMA0003 was higher than
that of TPMA0014 (Fig. 3). Furthermore, three unknown
peaks E-1, E-2, and E-3 were observed in the chromatogram
of the extract of TPMA0003 at 5.62, 6.95, and 6.28 min,
respectively. LC-MS was performed for the extract to
measure the molecular weight of these metabolites (E-1;
m/z 684, E-2; m/z 684, and E-3; m/z 698).
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The expression of the mycE gene would be controlled with
the mycCI intergenic mycCIp, which is located between mycF
and mycCI, because there is no promoter region immedi-
ately upstream of mycE. The amplified mycCIp and mycE
fragments were inserted into pSET152, and the resulting
plasmid pMG507 possessing the mycE gene under the
control of mycCIp was introduced into TPMA0003. The
resulting apramycin-resistant (aprr) transconjugant
TPMA0006 produced M-II (2.4 mg mL1), and the amount
of M-II produced by TPMA0006 was 14% of that produced
by the wild strain A11725. It was confirmed by PCR that
pMG507 was inserted into the artificial attB site on the
TPMA0003 chromosome by a site-specific recombination
between the attB site and the attP site derived from
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pSET152. Using the primers mycEF and 152intR annealing
outside attL and the primers 152attPF and MGneo860R
annealing outside attR, 0.4- and 1.2-kb fragments were
amplified from TPMA0006, respectively (Fig. 2b). These
results proved that site-specific recombination between the
artificial attB site and the attP derived from pSET152
occurred on the TPMA0003 chromosome. The existence of
mycE combined with mycCIp was also confirmed by PCR
with the primers mycCIPFNh and mycERBam annealing the
50-end region of mycCIp and the 30-end region of mycE,
respectively (Fig. 2b). Moreover, using the primers mycEF
and NeoFEV (annealing the 30-end region of neo), the 1.1-kb
amplified fragment – derived from TPMA0003 – was not
observed in the TPMA0006 lane (Fig. 2b). These results
indicated that the transconjugant TPMA0006 producing M-
II was the homogenous mycE complementation strain on
which the mycE gene under the control of mycCIp was
located at the artificial attB site on the chromosome.
Disruption and complementation of the mycF
gene
PCR targeting with the phage l-Red recombinase was used
to isolate the mycF disruption mutant. The mycF disruption
cassette was amplified with long PCR primers, mycFendF
and mycFendR, which included 39-nt targeting sequences
and 20- or 19-nt priming sequences. The priming sequences
of mycFendF and mycFendR were annealed at a part of the
attB site and a flanked region of the FRT site, respectively.
Replacement of mycF in pMG504 was achieved by the PCR-
amplified gene disruption cassette FRT-neo-oriT-FRT-attB
by electroporation into E. coli BW25113/pIJ790 containing
pMG504, and the resulting plasmid pMG505 was introduced
into A11725 by intergeneric conjugation. The resulting neor
and thios transconjugant TPMA0016 produced M-III, whose
productivity was the same as that of the following transcon-
jugant TPMA0004 (data not shown). Plasmid pMG506,
whose neo gene was in the same direction as the disrupted
mycF gene, was also introduced into A11725. The resulting
neor and thios transconjugant TPMA0004 was cultured in
FMM broth, and M-III was detected in the EtOAc of the
culture broth (7.9mg mL1, Fig. 3). Furthermore, two un-
known peaks F-1 and F-2 (5.33 and 10.7 min, respectively)
were detected in the extract of TPMA0004; the molecular
weight of these compounds was the same (m/z 698). When
PCR was performed for TPMA0004 and A11725 using the
primers mycFF and mycFCIendR annealing outside the FRT-
neo-oriT-FRT-attB cassette, different-sized fragments (2.2
and 1.3 kb, respectively) were observed in the agarose gel
(Fig. 2b). The difference in size indicated that TPMA0004
was the mycF disruption mutant.
For genetic complementation for the mycF disruption
mutant TPMA0004, pMG508 including mycF was transferred
to TPMA0004 by intergeneric conjugation. The transconju-
gant TPMA0009 isolated from the conjugation plate con-
taining apramycin and nalidixic acid produced M-II
(8.29mg mL1) (Fig. 3). The amount of M-II produced by
TPMA0009 was approximately 55% of that produced by the
wild strain A11725. PCR was performed with several primer
pairs to confirm the genetic condition of TPMA0009. As
shown in Fig. 2b, the transconjugant TPMA0009 producing
M-II was the homogenous mycF complementation strain in
which the mycF gene was inserted into the chromosome by a
site-specific recombination between the artificial attB site on
the chromosome and the attP site on pMG508.
Discussion
The disruption cassette FRT-neo-oriT-FRT-attB was used to
obtain the mycE disruption mutant TPMA0003 and the
mycF disruption mutant TPMA0004 of M. griseorubida. In
particular, PCR targeting with the phage l-Red recombinase
was performed to isolate the mycF disruption mutant.
Furthermore, from these mutants, the homogenous com-
plementation strains TPMA0003 and TPMA0004 were iso-
lated by a site-specific recombination between the artificial
attB site on the mutant chromosomes and the attP on
pSET152 used as a vector. Recently, a simple and highly
efficient PCR-targeting system was developed for the gene
targeting of Streptomyces strains (Gust et al., 2003). How-
ever, genetic engineering cannot be performed for actino-
mycete strains lacking the bacteriophage fC31 attB
attachment site using vectors possessing a fC31 int gene
and an attP site. In this study, gene disruption and
Fig. 2. (a) Physical maps of the region including mycE, mycF, and those flanking the genes on the chromosomes of wild strain Micromonospora griseorubida,
mycE and mycF disruption mutants, and the complementation strains. Oligonucleotide priming nucleotide sequences on the mycinamicin biosynthetic gene
cluster are shown as small arrows with lowercase alphabets: a, mycEF; b, mycERBam; c, 152intR; d, 152attPF; e, MGneo860F; f, mycCIPFNh; g, NeoFEV; h, mycFF;
i, mycFCIendR; j, mycCIPRNd; and k, mycEFNd. The relevant restriction sites (Ba, BamHI; Bs, BsiWI; EI, EcoRI; EV, EcoRV; M, MluI; Nd, NdeI; Nh, NheI; St, StuI; and
Xb, XbaI) are indicated. (b) Agarose gel electrophoresis of PCR products from wild strain M. griseorubida, mycE and mycF disruption mutants, and corresponding
complementation strains. The PCR product was separated by electrophoresis using a 1.6% agarose gel. Expected PCR fragments on each agarose gel are
indicated with arrows. Nonspecific fragments additionally appeared on the following lanes: a 0.5-kb fragment on lane 14 using primers a1b; a 0.5-kb fragment
on lane 3 using primers a1b; 0.5- and 0.6-kb fragments on lane 6 using primers d1e; 3.5- and 4.0-kb fragments on lane 4 using primers h1i; 0.5- and 0.6-kb
fragments on lane 9 using primers d1e; and a 2.5-kb fragment on lane 4 using primers h1g. Using primers d1e, an unexpected 1.0-kb fragment was observed
on lane 3. W, A11725 (wild); 3, TPMA0003 (DmycE), TPMA0014 (DmycE); 6, TPMA0006 (mycE complemented); 4, TPMA0004 (DmycF), TPMA0009 (mycF
complemented); and M, 500-bp ladder marker (MR500, Takara).
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complementation studies could be performed for M. gri-
seorubida, which lacked the bacteriophage fC31 attB site
on the chromosome, using the disruption cassette FRT-neo-
oriT-FRT-attB. A multiple gene disruption and complemen-
tation scheme using the disruption cassette is shown in Fig.
4. In this study, the complementation plasmid pMG508
possessing the int gene encoding integrase, the attP site, and
the resistant marker aac(3)IV was inserted into the fC31
attB attachment site, which was flanked by the resistant
marker neo and oriT on the mycF disruption mutant. For
additional gene disruption and complementation studies of
the complementation strain TPMA0009, resistant markers
other than neo and aac(3)IV should be used. However, if a
gene disruption mutant with the resistant marker eliminated
was obtained by in-frame disruption, additional gene dis-
ruption studies can be performed with the same resistant
marker. This multiple system would be a useful tool for
genetic engineering studies of not only actinomycete strains
lacking the attB site but also other strains possessing an attB
site, such as Streptomyces strains.
The mycE disruption mutant TPMA0003 and the mycF
disruption mutant TPMA0004 mainly produced the M-II
intermediates M-VI and M-III, respectively. Based on the
nucleotide sequence data, we have already proposed that the
genes mycE and mycF encode OMTs and that these OMT
proteins convert M-VI to M-III and M-III to M-IV, respec-
tively (Anzai et al., 2003). Moreover, based on enzymatic
studies, it was proved that MycE and MycF proteins catalyze
methylation at the C200-OH group of 6-deoxyallose in M-VI
and methylation at the C300-OH group of javose (i.e. C200-
methylated 6-deoxyallose) in M-III, respectively (Inouye
et al., 1994; Li et al., 2009). Therefore, the results from these
disruption mutants supported these previous studies. In the
EtOAc extract from the culture broth of TPMA0003, three
new minor peaks E-1, E-2, and E-3 were detected.
TPMA0003 had intact mycG genes, which encoded the
cytochrome P450 enzyme catalyzing both hydroxylation
and epoxidation at C14 and C12/13 on the macrolactone
ring of mycinamicin. The overexpressed MycG protein
recognized M-VI as its substrate (Anzai et al., 2008). There-
fore, the compounds of E-1 and E-2 were hypothesized to be
C14-hydroxy-M-VI and C12/13-epoxy-M-VI, respectively,
from their molecular weights, UV absorption spectra, and
retention times. C14-hydroxy-M-VI has already been pub-






























































Fig. 3. HPLC analysis of the EtOAc extract from Micromonospora
griseorubida culture broth. Micromonospora griseorubida A11725,
TPMA0014, TPMA0003, and TPMA0004 were cultured in 5 mL of FMM
broth at 27 1C for 10 days. Micromonospora griseorubida TPMA0006
and TPMA0009 were cultured in 5 mL of MR0.1S broth at 27 1C for 10
days. Chromatograms were scanned at 220 nm. UV lmax nm of peaks:
M-II, 218, 242 nm (sh); M-VI, 213, 284 nm; E-1, 216, 281 nm; E-2; 217,
242 nm (sh); E-3, 217, 281 nm; M-III, 215, 283 nm; F-1, 216, 281 nm;
and F-2, 218, 242 nm (sh).
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C12/13-epoxyl-M-VI has never been reported. Moreover,
TPMA0003 possesses the activity of methylation at the C300-
OH group of javose because the mycF gene was not
disrupted in this mutant. Accordingly, the MycF protein
would be able to recognize M-VI as its substrate and
methylate the C300-OH group of 6-deoxyallose on M-VI.
The compound E-3 was estimated to be hydroxylated
and methylated M-VI; these M-VI derivatives have never
been reported. Therefore, we should determine their mole-
cular structures in our future studies. Two new minor peaks
F-1 and F-2 were detected in the EtOAc extract from the
culture broth of TPMA0004. The overexpressed MycG
protein also recognized M-III as its substrate (Anzai et al.,
2008). C14-hydroxy-M-III has already been reported as
mycinamicin IX by Kinoshita et al. (1992), and C12/13-
epoxyl-M-III has also been reported by Mierzwa et al.
(1985). Therefore, the compounds of F-1 and F-2 were
estimated to be C14-hydroxy-M-III (M-IX) and C12/13-
epoxy-M-III, respectively.
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Fig. 4. Scheme of the multiple gene disruption and complementation method using the disruption cassette FRT-marker-oriT-FRT-attB. Step 1, PCR
targeting: a disruption template containing marker 1, oriT, P1, P2, two FRT sites, and attB is amplified by PCR using primers containing a 39-bp 5 0
homology region flanking the target gene (dotted lines a and b) and a 20-bp priming site (attB and P2 site). Then, the PCR product is transformed to
Escherichia coli BW25113/pIJ790 (expressing the l-Red recombination function) containing the plasmid with the cloned target gene. Step 2, Gene
disruption: the recombinant plasmid, whose target gene is replaced with the disruption cassette marker 1-oriT-attB, is transferred by intergeneric
conjugation from E. coli to the actinomycete strain. Selected actinomycete exconjugants are screened for resistance and susceptibility for two antibiotics
corresponding to marker 1 and marker 2, respectively. The double cross-over allelic exchange is confirmed by PCR. Step 3, Excision of the disruption
cassette: E. coli DH5a containing pCP20 was transformed with the recombinant plasmid, and FLP synthesis was induced. Step 4, In-frame deletion: the
recombinant plasmid, with loss of the disruption marker, is transferred to the gene-disrupted actinomycete mutant by intergeneric conjugation.
Exconjugants, resistant for an antibiotic corresponding to marker 2 and arising from single cross-over events, were restreaked nonselectively and
screened for the loss of resistance for the two antibiotics corresponding to marker 1 and marker 2, indicating a successful replacement by in-frame
deletion. The resulting exconjugants possess attB, P1, P2, and one FRTsite, which is located at the target gene on the chromosome of the actinomycete
strain. Step 5, Gene introduction: the transconjugation plasmid, possessing the fC31 int gene and an attP site with marker 3 and the extra and/or
complementation gene(s), is transferred to disruption mutants obtained in stages 2 and 4. Selected actinomycete exconjugants are screened for
resistance to an antibiotic corresponding to marker 3, and site-specific recombination between attB and attP sites is confirmed by PCR. Step 6, Repeat of
gene disruption and introduction: additional gene disruption and complementation studies can be performed with the same or other resistant markers
using the same scheme. The steps shown with the dashed line were not demonstrated in this study.
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